Continuity of Cancer Treatment Amidst the 2026 Gulf Regional Conflict: Insights and a Resilience Model from Gulf States - Top-Institutions - MDSpire

Continuity of Cancer Treatment Amidst the 2026 Gulf Regional Conflict: Insights and a Resilience Model from Gulf States

  • By

  • Humaid O. Al-Shamsi

  • Saeed Rafii

  • Maha Al Sindi

  • Ahmad Alhuraiji

  • Nedal Bukhari

  • Ibrahim Abu-Gheida

  • Deborah Mukherji

  • April 23, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Oncology
    • Global Health
    • Health Systems Research

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology
    • Health Policy
    • Global Oncology

  • #3

    The Institute of Cancer Research, London
    The Institute of Cancer Research, London

    London, N/A

    Key Differentiators

    • Oncology
    • Cancer Epidemiology
    • Health Systems

  • #4

    American University of Beirut Medical Center
    American University of Beirut Medical Center

    Beirut, N/A

    Key Differentiators

    • Oncology
    • Conflict Medicine
    • Health Systems

  • #5

    King Faisal Specialist Hospital & Research Centre
    King Faisal Specialist Hospital & Research Centre

    Riyadh, Saudi Arabia

    Key Differentiators

    • Oncology
    • Health Systems
    • Pharmaceutical Supply Chain

Original Source(s)

Continuity of Cancer Treatment Amidst the 2026 Gulf Regional Conflict: Insights and a Resilience Model from Gulf States

  • by Humaid O. Al-Shamsi, Saeed Rafii, Maha Al Sindi, Ahmad Alhuraiji, Nedal Bukhari, Ibrahim Abu-Gheida, Deborah Mukherji

  • April 23, 2026

Related Content

Recurrent pleuropulmonary blastoma type III initially misclassified as embryonal rhabdomyosarcoma on limited biopsy: a case report with pathogenic DICER1 variant

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy

Myelodysplastic syndromes complicated by atypical Sweet syndrome: a brief research report